Rankings / Hormones & Endocrine
PT-141 (Bremelanotide / Vyleesi)
Hormones & Endocrine · Melanocortin receptor agonist
Tier C+
Bottom line
Read Off Label grades PT-141 (Bremelanotide / Vyleesi) as C+ (5.5/10) based on moderate evidence, moderate benefit magnitude, and a med-risk safety profile.
AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common.
Typical use: 1. — Rx (Vyleesi, on-demand); research peptide gray market for off-label male use.
What this is
AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common. Off-label use in men for 'libido enhancement' popular in biohacker circles despite not being formally studied. Shares MC1R activity with Melanotan II — some tanning/darkening with repeated use.
Mechanism
Cyclic heptapeptide; non-selective melanocortin receptor agonist (MC3R, MC4R most relevant for sexual function); acts centrally to increase sexual desire; FDA-approved for premenopausal HSDD in women
Dose & route
1.75 mg subQ 45 min before sexual activity; max 8 doses/month
Citations
- https://pubmed.ncbi.nlm.nih.gov/31483222/
- https://pubmed.ncbi.nlm.nih.gov/32030885/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7379117/
- https://pubmed.ncbi.nlm.nih.gov/36291616/
- https://pubmed.ncbi.nlm.nih.gov/33684608/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does PT-141 (Bremelanotide / Vyleesi) work?
- Read Off Label rates the evidence for PT-141 (Bremelanotide / Vyleesi) as Moderate and the benefit magnitude as moderate, producing an overall grade of C+ (5.5/10). AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common.
- Is PT-141 (Bremelanotide / Vyleesi) safe?
- PT-141 (Bremelanotide / Vyleesi) has a med risk profile in published human data. Legal status: Rx (Vyleesi, on-demand); research peptide gray market for off-label male use. This is not medical advice — see the disclaimer.
- What is the typical dose for PT-141 (Bremelanotide / Vyleesi)?
- 1.75 mg subQ 45 min before sexual activity; max 8 doses/month
- How does PT-141 (Bremelanotide / Vyleesi) work?
- Cyclic heptapeptide; non-selective melanocortin receptor agonist (MC3R, MC4R most relevant for sexual function); acts centrally to increase sexual desire; FDA-approved for premenopausal HSDD in women
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.